Michael Barbella, Managing Editor08.04.23
At this year’s MedTech Conference powered by AdvaMed (Oct. 9-11), more than five dozen companies will present their respective innovations to gain access to industry and investor partnering opportunities.
The 61 startups comprising the MedTech Innovator 2023 Accelerator Cohort were whittled down from 1,150 companies that applied to participate in the program. Featuring medical device, diagnostic, and digital health companies worldwide, the 2023 Cohort members receive high visibility and access to leading medtech manufacturers, providers, investors, and other industry stakeholders. MedTech Innovator will additionally award $800,000 in non-dilutive funding to winners of its competitions throughout the 2023 program.
“We are proud of our track record of identifying and perfecting the most innovative medtech startups in the world. Since launching MedTech Innovator, more than 500 companies have completed the program, representing over 200 FDA approvals and clearances, and securing $6.8 billion in follow-on funding,” MedTech Innovator Founder/CEO Paul Grand said in a news release. “The 2023 MedTech Innovator Cohort once again includes passionate medtech entrepreneurs from around the globe. We look forward to working with our corporate partners and industry advisors over the course of the program, to help these startups advance their medical device, diagnostic and digital health innovations to improve patient care.”
From the Accelerator’s 1,150 applicants, MedTech Innovator, its corporate partners, and more than 400 industry judges advanced nearly 200 candidates to in-person pitch and partnering events on the MedTech Innovator Road Tour, where they met with over 300 evaluators representing leading industry stakeholders. This year’s cohort of 61 startups represent 21 U.S. states as well as Canada, Finland, France, Germany, Israel, Ireland, Japan, Kazakhstan, Luxembourg, Lithuania, Netherlands, Spain, Sweden, and the United Kingdom.
Of the 61 Cohort companies, at least a half-dozen are orthopedic related, including:
The 61 startups comprising the MedTech Innovator 2023 Accelerator Cohort were whittled down from 1,150 companies that applied to participate in the program. Featuring medical device, diagnostic, and digital health companies worldwide, the 2023 Cohort members receive high visibility and access to leading medtech manufacturers, providers, investors, and other industry stakeholders. MedTech Innovator will additionally award $800,000 in non-dilutive funding to winners of its competitions throughout the 2023 program.
“We are proud of our track record of identifying and perfecting the most innovative medtech startups in the world. Since launching MedTech Innovator, more than 500 companies have completed the program, representing over 200 FDA approvals and clearances, and securing $6.8 billion in follow-on funding,” MedTech Innovator Founder/CEO Paul Grand said in a news release. “The 2023 MedTech Innovator Cohort once again includes passionate medtech entrepreneurs from around the globe. We look forward to working with our corporate partners and industry advisors over the course of the program, to help these startups advance their medical device, diagnostic and digital health innovations to improve patient care.”
From the Accelerator’s 1,150 applicants, MedTech Innovator, its corporate partners, and more than 400 industry judges advanced nearly 200 candidates to in-person pitch and partnering events on the MedTech Innovator Road Tour, where they met with over 300 evaluators representing leading industry stakeholders. This year’s cohort of 61 startups represent 21 U.S. states as well as Canada, Finland, France, Germany, Israel, Ireland, Japan, Kazakhstan, Luxembourg, Lithuania, Netherlands, Spain, Sweden, and the United Kingdom.
Of the 61 Cohort companies, at least a half-dozen are orthopedic related, including:
- Adcura Inc., an Eden Prairie, Minn.-based firm that has developed minimally invasive implants to treat spine-related issues. The six-year-old company’s products include retractors, disposable accessories, and adjustable lumbar fusion devices; the devices address current surgical inefficiencies, enabling medical practitioners to maximize surgical efficiencies and minimize post-operative complications.
- Alyve Medical Inc., a Denver-headquartered creator of data-driven joint kinematics tools and personalized neuromuscular electrical stimulation (NMES) technologies. Its Neuralign S is a therapeutic Motion Activated Stimulation device that employs advanced sensor technology coupled with NMES to help patients recalibrate complex muscular movements and restore optimal joint motion and function. ShowMotion helps healthcare professionals track and evaluate patient movements with precision and in real time via a collection of non-invasive motion tracking sensors placed on the patient’s body.
- Fingy3D.com, a web application that aims to improve patient access to finger prosthetics after amputation. Fingy3D.com was released in Beta Mode in mid-May 2022 from Intermed Labs at Mon Health in Morgantown, W.V. Fingy3D allows users with distal finger amputations to take a photo of their missing fingertip and then receive a functional prosthetic in the mail in under a week. The Fingy can be 3D printed in several colors and materials, which the buyer can select after uploading a photo to the site.
- Renovos Biologics Ltd., a U.K. biologics company whose first product, RENOVITE, enables the use of bone-healing agents in a more precise, localized manner. The injectable BMP-2 gel is targeted for orthopaedic applications (spinal fusion, bone defects, ankle surgery). In early July, international medical devices firm Biocomposites took a minority interest in Renovos.
- ImmersiveTouch Inc., a Chicago firm building the digital surgery metaverse. Its Mission Rehearsal VR platform allows surgeons to virtually plan and simulate each patient’s unique anatomy in 3D before entering the operating room.
- Sparta Biomedical Inc., a Durham, N.C.-headquartered firm whose SBM-01 Biomimetic Implant has been granted FDA Breakthrough Device Designation. SBM-01 is intended to replace damaged knee cartilage in patients having single or multiple chondral or osteochondral defects in the knee.